Forum: Probiodrug » Probiodrug 2019 » Laatste pagina | Beursduivel.be

Probiodrug 2019

2.316 Posts, Pagina: « 1 2 3 4 5 6 ... 111 112 113 114 115 116 | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
Gala-diner
0
Lekker dagje met de handelsvoorraad, weer wat gratis aandeeltjes Probiodrug verdiend.
DeZwarteRidder
0
Zo zal het ook vergaan met Probio:
===============================================================
BioCryst down 49% premarket on underwhelming Phase 3 results for BCX7353
May 21, 2019 7:25 AM ET|About: BioCryst Pharmaceutica... (BCRX)|By: Douglas W. House, SA News Editor

BioCryst Pharmaceuticals (NASDAQ:BCRX) announces positive results from a Phase 3 clinical trial, APeX-2, evaluating plasma killikrein inhibitor BCX7353 for the prevention of hereditary angioedema (HAE) attacks.

The study met the primary endpoint for both doses (110 mg and 150 mg), reducing the rate of HAE attacks by 44% compared to placebo. Patients in the 150 mg arm with a baseline attack rate of <2/month experienced a 66% reduction versus control. Patients with an attack rate of 2 or more per month experienced a 40% reduction compared to control.

Investors are heading for the exits because the treatment benefit appears less than Takeda's (NYSE:TAK) TAKHZYRO (lanadelumab), approved in the U.S. in August 2018 and in Europe three months later. Patients receiving 150 mg - 300 mg experienced reductions in HAE attack rates of 76 - 87%.

Undeterred, BCRX plans to file a U.S. marketing application in Q4 followed by an application in Europe in Q1 2020.

Management will host a conference call this morning at 8:30 am ET to discuss the results.

Shares are down 49% premarket on increased volume.
Ookaanwezigbij...
0
quote:

DeZwarteRidder schreef op 16 mei 2019 om 16:14:


Alleen newbies en gladiolen denken dat het gebruik van veel dure woorden een garantie is voor succes.


PPPFFF....wat zit jou dwars man/vrouw???

Misschien verstandig om geen onnodige post meer te plaatsen hier en op andere forums.
Ookaanwezigbij...
0
quote:

Gala-diner schreef op 21 mei 2019 om 17:39:


Lekker dagje met de handelsvoorraad, weer wat gratis aandeeltjes Probiodrug verdiend.



Zo is het. Prima aandeel met een schommelde koers, is leuk verdienen zo haha. Jammer voor de zuurpruim DZR.
De opa van Juul
0
quote:

DeZwarteRidder schreef op 21 mei 2019 om 18:36:


Zo zal het ook vergaan met Probio:
===============================================================
BioCryst down 49% premarket on underwhelming Phase 3 results for BCX7353
May 21, 2019 7:25 AM ET|About: BioCryst Pharmaceutica... (BCRX)|By: Douglas W. House, SA News Editor

BioCryst Pharmaceuticals (NASDAQ:BCRX) announces positive results from a Phase 3 clinical trial, APeX-2, evaluating plasma killikrein inhibitor BCX7353 for the prevention of hereditary angioedema (HAE) attacks.

The study met the primary endpoint for both doses (110 mg and 150 mg), reducing the rate of HAE attacks by 44% compared to placebo. Patients in the 150 mg arm with a baseline attack rate of <2/month experienced a 66% reduction versus control. Patients with an attack rate of 2 or more per month experienced a 40% reduction compared to control.

Investors are heading for the exits because the treatment benefit appears less than Takeda's (NYSE:TAK) TAKHZYRO (lanadelumab), approved in the U.S. in August 2018 and in Europe three months later. Patients receiving 150 mg - 300 mg experienced reductions in HAE attack rates of 76 - 87%.

Undeterred, BCRX plans to file a U.S. marketing application in Q4 followed by an application in Europe in Q1 2020.

Management will host a conference call this morning at 8:30 am ET to discuss the results.

Shares are down 49% premarket on increased volume.



Wat een L*L vergelijking HAE is iets heel anders dan Alzheimer. HAE is een zeer zeldzame aandoening terwijl Alzheimer steeds meer voorkomt.
Gala-diner
0
quote:

DeZwarteRidder schreef op 21 mei 2019 om 18:36:


Zo zal het ook vergaan met Probio:
===============================================================
BioCryst down 49% premarket on underwhelming Phase 3 results for BCX7353
May 21, 2019 7:25 AM ET|About: BioCryst Pharmaceutica... (BCRX)|By: Douglas W. House, SA News Editor

BioCryst Pharmaceuticals (NASDAQ:BCRX) announces positive results from a Phase 3 clinical trial, APeX-2, evaluating plasma killikrein inhibitor BCX7353 for the prevention of hereditary angioedema (HAE) attacks.

The study met the primary endpoint for both doses (110 mg and 150 mg), reducing the rate of HAE attacks by 44% compared to placebo. Patients in the 150 mg arm with a baseline attack rate of <2/month experienced a 66% reduction versus control. Patients with an attack rate of 2 or more per month experienced a 40% reduction compared to control.

Investors are heading for the exits because the treatment benefit appears less than Takeda's (NYSE:TAK) TAKHZYRO (lanadelumab), approved in the U.S. in August 2018 and in Europe three months later. Patients receiving 150 mg - 300 mg experienced reductions in HAE attack rates of 76 - 87%.

Undeterred, BCRX plans to file a U.S. marketing application in Q4 followed by an application in Europe in Q1 2020.

Management will host a conference call this morning at 8:30 am ET to discuss the results.

Shares are down 49% premarket on increased volume.


Heb je al een duimpje ontvangen voor deze ijzersterke post?
fd183
0
DZR krijgt nooit duimpjes, alleen middelvingers, dat zou je inmiddels toch wel moeten weten. :-)
Gala-diner
0
Ik verwacht dat er deze week nog boven de €5 komen te staan.
Als het goede nieuws, wat ik spoedig verwacht, naar buiten gebracht wordt verwacht ik dat mijn 1e koersdoel van €15 voor mijn niet-handelsgedeelte op de borden zal staan.
fd183
0
Probiodrug to attend International Conferences in June 2019
Published: 22.05.19

HALLE (SAALE), Germany, 22 May 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), announces that the company is scheduled to attend the following conferences:



(1) 2019 BIO International Convention

June 3-6, 2019, Pennsylvania Convention Center, Philadelphia, PA, USA

Dr. Ulrich Dauer, CEO, and Dr. Michael Schaeffer, CBO, to attend and host meetings





(2) Biotech CEO Summit Europe

June 17-19, 2019, Enniskerry, Ireland

Dr. Ulrich Dauer, CEO, to attend

fd183
0
Is van ruim een maand geleden, maar toch.

„Probiodrug ist ein Technologieführer mit einem erfahrenen Management-Team und sehr soliden Knowhow- und IP-Positionen in Bezug auf neuartige Inhibitoren für krankheitsrelevante Enzyme. Das Unternehmen verfügt über einen überzeugenden Ansatz, Glutaminylcyclase als therapeutisches Ziel bei der Alzheimer-Krankheit und Krebs-Immuntherapie zu blockieren. Das neue Investorenkonsortium würdigt die Bedeutung des wissenschaftlichen Ansatzes von Probiodrug und die sorgfältige klinische Arbeit, die das Team zur Vorbereitung des Phase-2b-Programms für seinen Hauptwirkstoff PQ912 geleistet hat. “Kommentierte Dr. Claus Christiansen, Leiter des Konsortiums und Vorsitzender des Verwaltungsrats der Nordic Bioscience.


„Bisherige Misserfolge klinischer Studien von wichtigen Akteuren der Industrie haben gezeigt, wie dringend erforderlich Therapien der Alzheimer-Krankheit sind, die über die Amyloid-Hypothese hinausgehen. Probiodrug wird nicht aufgeben, um eine wirksame Therapie für Patienten zu finden. Mit PQ912 verfügen wir über einen einzigartigen und neuen Ansatz. Wir sind sehr stolz darauf, dass wir ein so erfahrenes Konsortium von Life-Science-Spezialisten gefunden haben, dessen langfristiges Engagement das klinische Phase-2b-Programm in Europa ermöglichen wird “, fügte Dr. Ulrich Dauer, CEO von Probiodrug hinzu.
DeZwarteRidder
0
quote:

fd183 schreef op 22 mei 2019 om 08:41:


DZR krijgt nooit duimpjes, alleen middelvingers, dat zou je inmiddels toch wel moeten weten. :-)

Ik krijg ook veel taarten aangeboden.......
DeZwarteRidder
0
fd183
0
quote:

DeZwarteRidder schreef op 22 mei 2019 om 17:44:


[...]
Ik krijg ook veel taarten aangeboden.......


Inderdaad! Lol
Bijlage:
Alex69
0
Wie was er ook al weer zo stellig dat de 4,90 een voorlopig, of zelfs helemaal niet te nemen horde was?
neet
0
[quote alias=DeZwarteRidder id=11609922 date=201905211836]
Zo zal het ook vergaan met Probio:
========================================================
BioCryst down 49% premarket on underwhelming Phase 3 results for BCX7353
May 21, 2019 7:25 AM ET|About: BioCryst Pharmaceutica... (BCRX)|By: Douglas W. House, SA News Editor

BioCryst Pharmaceuticals (NASDAQ:BCRX) announces positive results from a Phase 3 clinical trial, APeX-2, evaluating plasma killikrein inhibitor BCX7353 for the prevention of hereditary angioedema (HAE) attacks.

The study met the primary endpoint for both doses (110 mg and 150 mg), reducing the rate of HAE attacks by 44% compared to placebo. Patients in the 150 mg arm with a baseline attack rate of <2/month experienced a 66% reduction versus control. Patients with an attack rate of 2 or more per month experienced a 40% reduction compared to control.

Investors are heading for the exits because the treatment benefit appears less than Takeda's (NYSE:TAK) TAKHZYRO (lanadelumab), approved in the U.S. in August 2018 and in Europe three months later. Patients receiving 150 mg - 300 mg experienced reductions in HAE attack rates of 76 - 87%.

Undeterred, BCRX plans to file a U.S. marketing application in Q4 followed by an application in Europe in Q1 2020.

Management will host a conference call this morning at 8:30 am ET to discuss the results.

Shares are down 49% premarket on increased volume.

U antwoordt is wederom fout u bent de zwakste schakel hier op het forum
U kunt gaan tot ziens
2.316 Posts, Pagina: « 1 2 3 4 5 6 ... 111 112 113 114 115 116 | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 22-mei-19 17:35
Koers 4,930
Verschil +0,060 (+1,23%)
Hoog 4,930
Laag 4,760
Volume 32.408
Volume gemiddeld 67.914
Volume gisteren 55.340

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
# calculated realtime by Commerzbank & '^' by BNP Paribas, streaming powered by VWD Group